MicroVue™ BAP EIA
The MicroVue BAP EIA provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum.
Product Specifications
| Citations | 21 |
|---|---|
| Specimen |
Serum 20 μL |
| LLOQ | 2 U/L |
| ULOQ | 140 U/L |
| Assay Time | 3.5 hours |
| Cross Reactivity |
Baboon, Cow, Cynomolgous monkey, Dog, Goat, Horse, Rabbit, Rat, Rhesus monkey, Sheep |
Ordering Information
| Catalog Number | 8012 |
|---|---|
| Catalog Number (CE) | |
| Size | 96 wells/test |
| Price (USD) | $995.00 |
| Price (EURO) | 700,00 € |
Contact us
| US Phone | +1 (858) 552 1100 |
|---|---|
| EU Phone | +353 (91) 412 474 |
| US Email | contact-us@quidelortho.com |
| EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
| Description |
The MicroVue BAP EIA provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum. |
|---|---|
| Size | 96 wells/test |
| Form |
96 well plate with 12 eight-well strips in a resealable foil pouch |
| Specimen | Serum 20 μL |
| Limit of Detection (LOD) | 0.7 U/L |
| Lower Limit of Quantitation (LLOQ) | 2 U/L |
| Upper Limit of Quantitation (ULOQ) | 140 U/L |
| Intra Assay | 3.9–5.8% |
| Inter Assay | 5.0–7.6% |
| Standards | 6 |
| Controls | 2 |
| Sample Values |
Females (Ages 25–44) 11.6–29.6 U/L, Males (Ages ≥25) 15.0–41.3 U/L |
| Assay Time | 3.5 hours |
| Cross Reactivity |
Baboon, Cow, Cynomolgous monkey, Dog, Goat, Horse, Rabbit, Rat, Rhesus monkey, Sheep |
| Storage |
Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components |
| Background |
BAP is an enzyme produced by osteoblasts, the cells responsible for bone formation. The MicroVue BAP immunoassay provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum as an indicator of osteoblastic activity. Measurement of BAP is intended for use as an aid in the 1) management of postmenopausal osteoporosis and Paget's disease, 2) monitoring of postmenopausal women on hormonal or bisphosphonate therapy, and 3) prediction of skeletal response to hormonal therapy in postmenopausal women. |
